Advanced Breast Cancer Subset Can Now Be Treated with Lynparza in EU
The decision follows a recommendation by the Committee for Medicinal Products for Human Use (an arm of the European Medicines Agency), making Lynparza available for patients with Stage III or IV breast cancer, whose tumors are human epidermal growth factor receptor 2-negative (HER2-) and positive for BRCA gene mutations.
To receive Lynparza under this indication, patients need to have previously received chemotherapy — anthracycline and a taxane — either before or after surgery, unless they’re unsuitable for such treatments. Also, patients with hormone receptor (HR)-positive cancer should have been treated with or been considered unsuitable for hormone therapy.
Lynparza, developed jointly by AstraZeneca and Merck (known as MSD outside the U.S. and Canada), is a PARP enzyme inhibitor that blocks the DNA repair process in cells. Due to their faster division, cancer cells accumulate errors faster than healthy